Main picture: Former Rochester Drug Co-Operative CEO Laurence Doud III, leaves US. District Court in Manhattan yesterday.
The indictment unsealed Tuesday alleges former Rochester Drug Co-Operative CEO Laurence Doud III ordered subordinates to ignore red flags about certain pharmacy customers to maximize company revenues and his own pay, which more than doubled between 2012 and 2016 as the company’s sales of drugs like oxycodone and fentanyl skyrocketed.
Doud and other top executives “made the deliberate decision” not to investigate, monitor or alert federal regulators about pharmacy customers they knew were providing opioids to people who wanted them for non-medical uses, the indictment alleges.
Doud, 75, surrendered to authorities in New York City and is awaiting arraignment on two counts of conspiracy. His lawyer said he would fight the charges. If convicted, he faces a mandatory minimum sentence of 10 years in prison.
Rochester Drug Co-Operative and another former executive were also charged.
Rochester Drug Co-Operative’s oxycodone sales increased by 800% and its fentanyl sales jumped by 2,000% between 2012 and 2016, according to officials. During the same period, the company’s internal compliance office flagged 8,300 orders but reported just four to the U.S. Drug Enforcement Administration.
The company is one of the nation’s ten largest distributors of pharmaceutical products, with over 1,300 pharmacy customers and over $1 billion in revenue per year. The company says the vast majority of its customers are small, independent pharmacies.
The Rochester, New York-based company will pay a $20 million fine to resolve a civil complaint and consented to three years of independent compliance monitoring.
Doud, who retired in 2017, alleged in a lawsuit last year that Rochester Drug Co-Operative tried using him as a scapegoat for its legal and regulatory troubles.
To receive similar content, “Like” us on Facebook @ https://www.facebook.com/niagarabuzz.ca
